Home › Crohn's Disease
Crohn's Disease clinical trials recruiting in the U.S.
93 studies for Crohn's Disease are recruiting participants at sites across the United States.
Crohn's Disease can cause inflammation in any area from the mouth to the anus. Read about medicines, surgery or dietary management to treat symptoms.
Cities with the most studies
- New York City, NY35 studies
- Miami, FL19 studies
- Boston, MA19 studies
- St. Louis, MO19 studies
- Cleveland, OH18 studies
- Atlanta, GA17 studies
- Orlando, FL17 studies
- Houston, TX17 studies
- Tyler, TX16 studies
- Los Angeles, CA15 studies
- San Diego, CA15 studies
- San Antonio, TX15 studies
- Colorado Springs, CO13 studies
- Philadelphia, PA13 studies
- Durham, NC12 studies
- Providence, RI12 studies
- Pittsburgh, PA11 studies
- Tacoma, WA11 studies
- Seattle, WA11 studies
- Cincinnati, OH11 studies
- Baltimore, MD10 studies
- Lubbock, TX10 studies
- Tampa, FL10 studies
- Washington, DC10 studies
- Indianapolis, IN10 studies
- Louisville, KY9 studies
- Lewisville, TX9 studies
- Evanston, IL9 studies
- Chicago, IL9 studies
- Dallas, TX9 studies
- Ann Arbor, MI9 studies
- New Haven, CT8 studies
- Charlotte, NC8 studies
- Rochester, MN8 studies
- Independence, MO8 studies
- Columbus, OH8 studies
- Oklahoma City, OK7 studies
- Lancaster, CA7 studies
- Lafayette, LA7 studies
- Queens, NY7 studies
By state
- Alabama9 studies
- Arizona17 studies
- Arkansas3 studies
- California37 studies
- Colorado18 studies
- Connecticut14 studies
- District of Columbia4 studies
- Florida27 studies
- Georgia22 studies
- Idaho4 studies
- Illinois18 studies
- Indiana12 studies
- Iowa8 studies
- Kansas11 studies
- Kentucky12 studies
- Louisiana11 studies
- Maryland15 studies
- Massachusetts27 studies
- Michigan19 studies
- Minnesota11 studies
- Mississippi3 studies
- Missouri21 studies
- Nevada8 studies
- New Hampshire3 studies
- New Jersey9 studies
- New York36 studies
- North Carolina20 studies
- Ohio29 studies
- Oklahoma8 studies
- Oregon4 studies
- Pennsylvania23 studies
- Rhode Island12 studies
- South Carolina11 studies
- South Dakota4 studies
- Tennessee10 studies
- Texas36 studies
- Utah8 studies
- Virginia15 studies
- Washington22 studies
- Wisconsin7 studies
Recently updated studies
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07697456A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 29, 2026 · NCT06430801Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
RecruitingObservational study
Ages 18 to 85 · All sexes · Updated Sep 29, 2026 · NCT07619547A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07499232A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06233461A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07196722A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 25, 2026 · NCT05923073Non-nutritive Sweeteners in Inflammatory Bowel Disease
RecruitingHealthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Sep 25, 2026 · NCT07769437A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
RecruitingPhase 3
Ages 3 and older · All sexes · Updated Sep 25, 2026 · NCT06663332Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT06548542Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease
Recruiting
Ages 16 to 75 · All sexes · Updated Sep 24, 2026 · NCT07671872Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT06937099A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184944An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
Ages 16 to 80 · All sexes · Updated Sep 23, 2026 · NCT07184931Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT03816345A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
RecruitingPhase 3
Ages 2 to 17 · All sexes · Updated Sep 23, 2026 · NCT05995353A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483099A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 22, 2026 · NCT06226883A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07483073A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
RecruitingPhase 3
Ages 2 to 19 · All sexes · Updated Sep 22, 2026 · NCT04844606A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
RecruitingPhase 4
Ages 18 to 80 · All sexes · Updated Sep 15, 2026 · NCT06581328A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated Sep 9, 2026 · NCT06045754Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)
RecruitingPhase 3
All ages · All sexes · Updated Sep 9, 2026 · NCT06651281Standardized Microbiota Transplant Therapy in Crohn's Disease
RecruitingPhase 2
Ages 18 to 89 · All sexes · Updated Sep 8, 2026 · NCT06631586DB-3Q for the Treatment of Medically Refractory Crohn's Disease
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 1, 2026 · NCT07625293From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.